Axonyx continues phenserine evaluation
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Axonyx believes a subgroup analysis of failed Phase III trials for its Alzheimer's therapy phenserine supports its position that higher doses of the treatment "could potentially be efficacious in treating the signs and symptoms of mild to moderate AD in future potential Phase III trials," the firm says Nov. 29. In a subgroup of patients receiving phenserine 15 mg twice daily, a statistically significant benefit over placebo was seen in the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog). "This additional analysis was recently completed as part of the program to identify a partner for the further development of phenserine," Axonyx says. Axonyx initially announced disappointing results for phenserine in February, then again in September (Pharmaceutical Approvals Monthly October 2005, In Brief)...